Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

BIOARCTIC AB

31.78
0.0000
Volume:- -
Turnover:- -
Market Cap:2.82B
PE:-245.51
High:31.78
Open:31.78
Low:31.78
Close:31.78
52wk High:40.00
52wk Low:22.87
Shares:88.64M
Float Shares:88.64M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.21
Dividend Rate:0.65%
EPS(TTM):-0.1294
EPS(LYR):0.2584
ROE:10.32%
ROA:12.88%
PB:12.46
PE(LYR):123.00

Loading ...

OverviewCompanyNewsFilings

Subcutaneous Leqembi Autoinjector Matches IV Exposure, Promises More Flexible Alzheimer’s Care

TIPRANKS
·
Jul 13

Eli Lilly, BioArctic enter research pact for BrainTransporter combination

TIPRANKS
·
Jun 22

Eli Lilly, BioArctic Sign Neurodegeneration Research Deal Worth Up to $800 Million

MT Newswires Live
·
Jun 22

BioArctic's Fourth BrainTransporter Deal Signals Growing Platform Value -- Market Talk

Dow Jones
·
Jun 22

BioArctic AGM Backs Dividend, New Share Mandate and Employee Incentive Plan

TIPRANKS
·
May 29

Eisai Sees Strong 2028 Sales Potential for BioArctic’s Alzheimer’s Drug Leqembi

TIPRANKS
·
May 25

BioArctic lifts royalties and milestones as Leqembi expands globally amid mixed regulatory signals

TIPRANKS
·
May 20

BioArctic Showcases Leqembi Momentum and BrainTransporter Deals in 2025 Report

TIPRANKS
·
Apr 22

BioArctic Nomination Committee Proposes Strengthened Board Ahead of 2026 AGM

TIPRANKS
·
Mar 27

BioArctic Updates Share Count After Stock Option Exercise

TIPRANKS
·
Feb 28

BioArctic Enters “Growth Era” on Record 2025 and Expanding Leqembi Reach

TIPRANKS
·
Feb 18

BioArctic Sets February 18 Release and Investor Call for Q4 2025 Report

TIPRANKS
·
Feb 11

BioArctic Royalty Income Climbs on Rising Global Sales of Alzheimer’s Drug Leqembi

TIPRANKS
·
Feb 06

BioArctic and Eisai Win FDA Priority Review for At‑Home Leqembi Autoinjector Start Dosing

TIPRANKS
·
Jan 26